Heidelberg University
uni-heidelberg.deTotal trials
285
Active
16
Phase 3
23
Total enrollment
63,621
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Standard | — | — | — | — | — | 1 | |
| Experimental | — | — | — | — | — | 1 | |
| Anakinra | — | — | — | — | — | 1 |
Next readouts
- 2026-12-01
- 2027-09-30
Top conditions
- Healthy12
- Pulmonary Hypertension10
- Depression6
- Malaria6
- COPD5
- Pharmacokinetics5
- Ulcerative Colitis4
- Cerebral Palsy4
Frequently asked questions about Heidelberg University
- How many clinical trials does Heidelberg University have on ClinicalTrials.gov?
- Heidelberg University is listed as the lead sponsor on 285 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Heidelberg University's trials are in Phase 3?
- 23 of Heidelberg University's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Heidelberg University focus on?
- Heidelberg University's most-studied conditions on ClinicalTrials.gov are Healthy, Pulmonary Hypertension, Depression, Malaria, COPD.
- When are Heidelberg University's next clinical trial readouts?
- Heidelberg University has 2 upcoming primary-completion readouts tracked here; the soonest is “A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF”, expected around 2026-12-01.